The IP assets of Civetta Therapeutics, LLC will be sold in an ABC sale. Civetta Therapeutics is a pioneering bio-tech research firm that exploits the therapeutic potential of β-propeller proteins. Civetta ceased business operations and entered into an Assignment for the Benefit of Creditors on December 22, 2023. The available intellectual property portfolio encompasses research by Civetta in a niche area of biotechnology, offering a unique opportunity for entities interested in this field to acquire a comprehensive portfolio of intellectual property with vast therapeutic and commercial potential. Bids must be submitted no later than April 30th at 5:00 pm CT. For more information, read the full public notice here on DailyDAC.
|